Clinical trial
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified…
NCT00078520 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00078520 |
|---|---|
| Title | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells |
| Official title | Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA) |
| Acronym | CLIPA |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, B-Cell, Chronic |
| Intervention type | Biological |
| Interventions | Dose Level 1, Dose Level 2, Dose Level 2- Fixed Dose |
| Enrollment | 9 |
| Start date | Jan 1, 2003 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Mar 2, 2004 |
| Last update posted | Jan 21, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: